Skip to content

being and becoming in the world

About me
being and becoming
in the world
Mind The Gap
where time passes (listen)

Search for:

Search for:

Tag: paid opinion leaders are a blot on medicine’s integrity and we should make them a thing of the past

By Hole Ousia Posted on December 6, 2023

Anti-amyloid drugs: Key questions

As published here.

Categories: Alzheimer's disease, Dementia, History of medicine, Medical Education, Medical writings, Neuro-imaging, Neuro-protection, NHS Scotland, Pharmaceutical industry and Medical Education, ScreeningTags: 'The Edinburgh Consensus: Preparing for the advent of disease-modifying therapies for Alzheimer's disease' Alzheimer's research & therapy, 11 May 2023 - Donanemab - Eli Lilly, 17 July 2023, 2023;382:p1852, 21 May 2023, 385;7, a blot a stain or perhaps something worse, a drug that is not effective cannot be cost-effective, A Sunshine Act for Scotland, ABPI, Accelerated approval of anti-amyloid drugs, accelerated approval pathway, Aducanumab and Donanemab for Early Alzheimer Disease: Estimating the true value, Adverts for 'Scottish Brain Sciences', Alberto J Espay, Alette M Wessels, Alzheimer, Alzheimer Scotland, Alzheimer Scotland: Annual Conference 2023, Alzheimer Society, Alzheimer's, Alzheimer's disease, Alzheimer's Drug Trial, Alzheimer's Drug Trial: What promising results means for treatments, Alzheimer's Society, Amar H kelkar, amylod, amyloid cascade, AMYVID, Association of the British Pharmaceutical Industry, August 2021, ‘Evidence Based Medicine’ or ‘Industry Biased Medicine’, ‘Looking to a brighter future’ – how today’s research, Baroness Cumberlege, BBC, Big Pharma, Blazing trails or the road to nowhere?, bleeding, bleeding and seizures, BMJ, BMJ 2008;336:1402, BMJ 2018;360:k135, BMJ 2023;382:p1659, brain swelling, Brain volume loss due to Donanemab, Caroline Wilson, CEO and Founder of Scottish Brain Sciences, Chief Executive of Alzheimer’s Research UK, competing interests, cost-effectiveness of Aducanumab and Donanemab, Craig Ritchie, Cumberlege Review, Dawn A Brooks, Dawn Brooks, declaration, declarations, Declarations of Interest, definitions, Dementia, Dementia expert Professor Craig Ritchie quits NHS job, Dementia's Medical-Industrial-Charity Complex, Disclosure UK, disease modification, disease mongering, disease-modifying, Donanemab, Donanemab in Early Symptomatic Alzheimer Disease, Donanemab leads to modest slowing of Alzheimer’s progression, Donanemab: bleeding and seizures, Donanemab:'The results may be misleading', Dr Alan Duncan, Dr Margaret McCartney, Dr Peter Gordon, Dr Peter J Gordon, early Alzheimer's disease, early diagnosis, early diagnosis is everywhere, early diagnosis of dementia, Edinburgh, Edinburgh Consensus, Edward R Scheffer Cliff, Eli Lilly, EPAD, Eric L Ross, Estimating the true value: Aducanumab and Donanemab for Early Alzheimer Disease, European Journal of Neurology, Expert reaction to approval of ADUCANUMAB, Express, FDA, first do no harm, fully informed consent, Gareth Iacobucci, General Medical Council, Glasgow Declaration, GMC, Good Medical Practice, headlines, Henry Simmons, Here’s a game: try and find a doctor’s conflicts of interest., Hide and Seek, Hiding and seeking doctors’ conflicts of interest, Hilary Evans, Hole Ousia, https://www.alzscot.org/conference23, immunoglobulin G1, independent experts or drug representatives in disguise, informed consent, infusion, Issues not considered in the 'Edinburgh Consensus', Jill Manthorpe, John R Sims, Key Opinion Leaders, Key opinion leaders and Industry, Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease, Keynote Lecture, learning and developments are offering hope for tomorrow, Marc Aurel Busche, Marc S Weinberg, Maree Todd, Mark A Mintun, MCI, Medical-Industrial-Charity Complex, Melbourne Dementia Research Centre, MHRA, mild cognitive impairment, Mintun et al, Mirror, monoclonal antibody, Monopoly, MSP, Narrative Controllers, Nature, New treatments for Alzheimer's disease, New York Times, newspaper reports, NICE guidelines, No Holds barred, No sunshine for Scotland, oining the world's first Brain Health Community, paid opinion leaders, paid opinion leaders are a blot on medicine’s integrity and we should make them a thing of the past, PE1493, pharma, Pharmaceutical Industry, Phase 3, placebo-controlled trial of Donanemab, PMCPA, preclinical Alzheimers, preclinical dementia, Prescription Medicines Code of Practice Authority, prevention, primum non nocere, prodromal dementia, Prof Ritchie said: "“We understand the disease, Prof Rob Howard, Prof Robert Howard, Professor Craig Ritchie, Professor Rob Howard, Professor Robert Howard, public health, radio 4, Ray Moynihan, RCPsych, RCT, Realistic Medicine, rebel antiquary, Registers of Interest, regulatory approval, research, Royal College of Psychiatrists, Sara Reardon, scanners, Science Media Centre, Scott Aytoun, Scottish Brain Sciences, Sebastian Walsh, seizures, side effects, Sky News, Snakes and ladders, snakes ladders and Monopoly, Soeren Mattke, Steve Illiffe, Steven E Arnold, study finds, Sunshine Act for Scotland, Sunshine legislation, t's boom time in industry, tau, The Edinburgh Consensus, the evidence of benefit probably does not outweigh the negatives, The Guardian, The hyperbole in the media and scientific response is unjustified and cruel to patients, The Narrative Controllers, The New England Journal of Medicine, The Rebel Antiquary, The report of the Independent Medicines and Medical Devices Safety Review, The World Tonight, timely diagnosis, timely diagnosis of dementia, Tom Russ, Too much Medicine, trailblazer, TRAILBLAZER-ALZ 2, Transparency, treatments for Alzheimer's disease, University of Cincinnati, US Food and Drug Administration, Vol 617, we understand what is is going on in the brain", worldwide trailblazing headlines of the latest anti-amyloid drug

By Hole Ousia Posted on December 6, 2023

Accelerated approval of anti-amyloid drugs

I fully share the concerns expressed by Professor Robert Howard:

Categories: Alzheimer's disease, Dementia, History of medicine, Medical Education, Medical writings, Neuro-imaging, Neuro-protection, ScreeningTags: 'The Edinburgh Consensus: Preparing for the advent of disease-modifying therapies for Alzheimer's disease' Alzheimer's research & therapy, 11 May 2023 - Donanemab - Eli Lilly, 17 July 2023, 2023;382:p1852, 21 May 2023, 385;7, a blot a stain or perhaps something worse, a drug that is not effective cannot be cost-effective, A Sunshine Act for Scotland, ABPI, Accelerated approval of anti-amyloid drugs, accelerated approval pathway, Aducanumab and Donanemab for Early Alzheimer Disease: Estimating the true value, Adverts for 'Scottish Brain Sciences', Alberto J Espay, Alette M Wessels, Alzheimer, Alzheimer Scotland, Alzheimer Scotland: Annual Conference 2023, Alzheimer Society, Alzheimer's, Alzheimer's disease, Alzheimer's Drug Trial, Alzheimer's Drug Trial: What promising results means for treatments, Alzheimer's Society, Amar H kelkar, amylod, amyloid cascade, AMYVID, Association of the British Pharmaceutical Industry, August 2021, ‘Evidence Based Medicine’ or ‘Industry Biased Medicine’, ‘Looking to a brighter future’ – how today’s research, Baroness Cumberlege, BBC, Big Pharma, Blazing trails or the road to nowhere?, bleeding, bleeding and seizures, BMJ, BMJ 2008;336:1402, BMJ 2018;360:k135, BMJ 2023;382:p1659, brain swelling, Brain volume loss due to Donanemab, Caroline Wilson, CEO and Founder of Scottish Brain Sciences, Chief Executive of Alzheimer’s Research UK, competing interests, cost-effectiveness of Aducanumab and Donanemab, Craig Ritchie, Cumberlege Review, Dawn A Brooks, Dawn Brooks, declaration, declarations, Declarations of Interest, definitions, Dementia, Dementia expert Professor Craig Ritchie quits NHS job, Dementia's Medical-Industrial-Charity Complex, Disclosure UK, disease modification, disease mongering, disease-modifying, Donanemab, Donanemab in Early Symptomatic Alzheimer Disease, Donanemab leads to modest slowing of Alzheimer’s progression, Donanemab: bleeding and seizures, Donanemab:'The results may be misleading', Dr Alan Duncan, Dr Margaret McCartney, Dr Peter Gordon, Dr Peter J Gordon, early Alzheimer's disease, early diagnosis, early diagnosis is everywhere, early diagnosis of dementia, Edinburgh, Edinburgh Consensus, Edward R Scheffer Cliff, Eli Lilly, EPAD, Eric L Ross, Estimating the true value: Aducanumab and Donanemab for Early Alzheimer Disease, European Journal of Neurology, Expert reaction to approval of ADUCANUMAB, Express, FDA, first do no harm, fully informed consent, Gareth Iacobucci, General Medical Council, Glasgow Declaration, GMC, Good Medical Practice, headlines, Henry Simmons, Here’s a game: try and find a doctor’s conflicts of interest., Hide and Seek, Hiding and seeking doctors’ conflicts of interest, Hilary Evans, Hole Ousia, https://www.alzscot.org/conference23, immunoglobulin G1, independent experts or drug representatives in disguise, informed consent, infusion, Issues not considered in the 'Edinburgh Consensus', Jill Manthorpe, John R Sims, Key Opinion Leaders, Key opinion leaders and Industry, Keynote Lecture, learning and developments are offering hope for tomorrow, Marc Aurel Busche, Marc S Weinberg, Maree Todd, Mark A Mintun, MCI, Medical-Industrial-Charity Complex, Melbourne Dementia Research Centre, MHRA, mild cognitive impairment, Mintun et al, Mirror, monoclonal antibody, Monopoly, MSP, Narrative Controllers, Nature, New treatments for Alzheimer's disease, New York Times, newspaper reports, NICE guidelines, No Holds barred, No sunshine for Scotland, oining the world's first Brain Health Community, paid opinion leaders, paid opinion leaders are a blot on medicine’s integrity and we should make them a thing of the past, PE1493, pharma, Pharmaceutical Industry, Phase 3, placebo-controlled trial of Donanemab, PMCPA, preclinical Alzheimers, preclinical dementia, Prescription Medicines Code of Practice Authority, prevention, primum non nocere, prodromal dementia, Prof Ritchie said: "“We understand the disease, Prof Rob Howard, Prof Robert Howard, Professor Craig Ritchie, Professor Rob Howard, Professor Robert Howard, public health, radio 4, Ray Moynihan, RCPsych, RCT, Realistic Medicine, rebel antiquary, Registers of Interest, regulatory approval, research, Royal College of Psychiatrists, Sara Reardon, scanners, Science Media Centre, Scott Aytoun, Scottish Brain Sciences, Sebastian Walsh, seizures, side effects, Sky News, Snakes and ladders, snakes ladders and Monopoly, Soeren Mattke, Steve Illiffe, Steven E Arnold, study finds, Sunshine Act for Scotland, Sunshine legislation, t's boom time in industry, tau, The Edinburgh Consensus, the evidence of benefit probably does not outweigh the negatives, The Guardian, The hyperbole in the media and scientific response is unjustified and cruel to patients, The Narrative Controllers, The New England Journal of Medicine, The Rebel Antiquary, The report of the Independent Medicines and Medical Devices Safety Review, The World Tonight, timely diagnosis, timely diagnosis of dementia, Tom Russ, Too much Medicine, trailblazer, TRAILBLAZER-ALZ 2, Transparency, treatments for Alzheimer's disease, University of Cincinnati, US Food and Drug Administration, Vol 617, we understand what is is going on in the brain", worldwide trailblazing headlines of the latest anti-amyloid drug

By Hole Ousia Posted on December 6, 2023December 6, 2023

Dementia’s Medical-Industrial-Charity Complex

A BMJ rapid response: Personal comment: I fully share the concerns set out in this BMJ response. Alas, Scotland seems to be determined to be set to ‘go’: Keynote Lecture, … Continue reading Dementia’s Medical-Industrial-Charity Complex

Categories: Alzheimer's disease, British Medical Journal, Dementia, History of medicine, Medical Education, Medical writings, Neuro-imaging, Neuro-protection, NHS Hospitality Registers, NHS Scotland, Pharmaceutical industry and Medical Education, Psychiatry, Screening, Sunshine Act for ScotlandTags: 'The Edinburgh Consensus: Preparing for the advent of disease-modifying therapies for Alzheimer's disease' Alzheimer's research & therapy, 11 May 2023 - Donanemab - Eli Lilly, 17 July 2023, 2023;382:p1852, 21 May 2023, 385;7, a blot a stain or perhaps something worse, a drug that is not effective cannot be cost-effective, A Sunshine Act for Scotland, ABPI, Accelerated approval of anti-amyloid drugs, accelerated approval pathway, Aducanumab and Donanemab for Early Alzheimer Disease: Estimating the true value, Adverts for 'Scottish Brain Sciences', Alberto J Espay, Alette M Wessels, Alzheimer, Alzheimer Scotland, Alzheimer Scotland: Annual Conference 2023, Alzheimer Society, Alzheimer's, Alzheimer's disease, Alzheimer's Drug Trial, Alzheimer's Drug Trial: What promising results means for treatments, Alzheimer's Society, Amar H kelkar, amylod, amyloid cascade, AMYVID, anti-amyloid drugs: key questions, Association of the British Pharmaceutical Industry, August 2021, ‘Evidence Based Medicine’ or ‘Industry Biased Medicine’, ‘Looking to a brighter future’ – how today’s research, Baroness Cumberlege, BBC, Big Pharma, Blazing trails or the road to nowhere?, bleeding, bleeding and seizures, BMJ, BMJ 2008;336:1402, BMJ 2018;360:k135, BMJ 2023;382:p1659, brain swelling, Brain volume loss due to Donanemab, Caroline Wilson, CEO and Founder of Scottish Brain Sciences, Chief Executive of Alzheimer’s Research UK, competing interests, cost-effectiveness of Aducanumab and Donanemab, Craig Ritchie, Cumberlege Review, Dawn A Brooks, Dawn Brooks, declaration, declarations, Declarations of Interest, definitions, Dementia, Dementia expert Professor Craig Ritchie quits NHS job, Dementia's Medical-Industrial-Charity Complex, Disclosure UK, disease modification, disease mongering, disease-modifying, Donanemab, Donanemab in Early Symptomatic Alzheimer Disease, Donanemab leads to modest slowing of Alzheimer’s progression, Donanemab: bleeding and seizures, Donanemab:'The results may be misleading', Dr Alan Duncan, Dr Margaret McCartney, Dr Peter Gordon, Dr Peter J Gordon, early Alzheimer's disease, early diagnosis, early diagnosis is everywhere, early diagnosis of dementia, Edinburgh, Edinburgh Consensus, Edward R Scheffer Cliff, Eli Lilly, EPAD, Eric L Ross, Estimating the true value: Aducanumab and Donanemab for Early Alzheimer Disease, European Journal of Neurology, Express, FDA, first do no harm, fully informed consent, Gareth Iacobucci, General Medical Council, Glasgow Declaration, GMC, Good Medical Practice, headlines, Henry Simmons, Here’s a game: try and find a doctor’s conflicts of interest., Hide and Seek, Hiding and seeking doctors’ conflicts of interest, Hilary Evans, Hole Ousia, https://www.alzscot.org/conference23, immunoglobulin G1, independent experts or drug representatives in disguise, informed consent, infusion, Issues not considered in the 'Edinburgh Consensus', Jill Manthorpe, John R Sims, Key Opinion Leaders, Key opinion leaders and Industry, Keynote Lecture, learning and developments are offering hope for tomorrow, Marc Aurel Busche, Marc S Weinberg, Maree Todd, Mark A Mintun, MCI, Medical-Industrial-Charity Complex, Melbourne Dementia Research Centre, MHRA, mild cognitive impairment, Mintun et al, Mirror, monoclonal antibody, Monopoly, MSP, Narrative Controllers, Nature, New treatments for Alzheimer's disease, New York Times, newspaper reports, NICE guidelines, No Holds barred, No sunshine for Scotland, oining the world's first Brain Health Community, paid opinion leaders, paid opinion leaders are a blot on medicine’s integrity and we should make them a thing of the past, PE1493, pharma, Pharmaceutical Industry, Phase 3, placebo-controlled trial of Donanemab, PMCPA, preclinical Alzheimers, preclinical dementia, Prescription Medicines Code of Practice Authority, prevention, primum non nocere, prodromal dementia, Prof Ritchie said: "“We understand the disease, Prof Rob Howard, Prof Robert Howard, Professor Craig Ritchie, Professor Rob Howard, Professor Robert Howard, public health, radio 4, Ray Moynihan, RCPsych, RCT, Realistic Medicine, rebel antiquary, Registers of Interest, regulatory approval, research, Royal College of Psychiatrists, Sara Reardon, scanners, Scott Aytoun, Scottish Brain Sciences, Sebastian Walsh, seizures, side effects, Sky News, Snakes and ladders, snakes ladders and Monopoly, Soeren Mattke, Steve Illiffe, Steven E Arnold, study finds, Sunshine Act for Scotland, Sunshine legislation, t's boom time in industry, tau, The Edinburgh Consensus, the evidence of benefit probably does not outweigh the negatives, The Guardian, The hyperbole in the media and scientific response is unjustified and cruel to patients, The Narrative Controllers, The New England Journal of Medicine, The Rebel Antiquary, The report of the Independent Medicines and Medical Devices Safety Review, The World Tonight, timely diagnosis, timely diagnosis of dementia, Tom Russ, Too much Medicine, trailblazer, TRAILBLAZER-ALZ 2, Transparency, treatments for Alzheimer's disease, University of Cincinnati, US Food and Drug Administration, Vol 617, we understand what is is going on in the brain", worldwide trailblazing headlines of the latest anti-amyloid drug

By Hole Ousia Posted on December 6, 2023

Blazing trails or the road to nowhere?

As published in the BMJ, 22 August 2023:

Categories: Alzheimer's disease, British Medical Journal, Dementia, History of medicine, Medical Education, Medical writings, Neuro-imaging, Neuro-protection, NHS Hospitality Registers, NHS Scotland, Pharmaceutical industry and Medical Education, PsychiatryTags: 'The Edinburgh Consensus: Preparing for the advent of disease-modifying therapies for Alzheimer's disease' Alzheimer's research & therapy, 11 May 2023 - Donanemab - Eli Lilly, 17 July 2023, 2023;382:p1852, 21 May 2023, 385;7, a blot a stain or perhaps something worse, a drug that is not effective cannot be cost-effective, A Sunshine Act for Scotland, ABPI, accelerated approval pathway, Aducanumab and Donanemab for Early Alzheimer Disease: Estimating the true value, Adverts for 'Scottish Brain Sciences', Alberto J Espay, Alette M Wessels, Alzheimer, Alzheimer Scotland, Alzheimer Scotland: Annual Conference 2023, Alzheimer Society, Alzheimer's, Alzheimer's disease, Alzheimer's Drug Trial, Alzheimer's Drug Trial: What promising results means for treatments, Alzheimer's Society, Amar H kelkar, amylod, amyloid cascade, AMYVID, Association of the British Pharmaceutical Industry, August 2021, ‘Evidence Based Medicine’ or ‘Industry Biased Medicine’, ‘Looking to a brighter future’ – how today’s research, Baroness Cumberlege, BBC, Big Pharma, Blazing trails or the road to nowhere?, bleeding, bleeding and seizures, BMJ, BMJ 2008;336:1402, BMJ 2018;360:k135, BMJ 2023;382:p1659, brain swelling, Brain volume loss due to Donanemab, Caroline Wilson, CEO and Founder of Scottish Brain Sciences, Chief Executive of Alzheimer’s Research UK, competing interests, cost-effectiveness of Aducanumab and Donanemab, Craig Ritchie, Cumberlege Review, Dawn A Brooks, Dawn Brooks, declaration, declarations, Declarations of Interest, definitions, Dementia, Dementia expert Professor Craig Ritchie quits NHS job, Disclosure UK, disease modification, disease mongering, disease-modifying, Donanemab, Donanemab in Early Symptomatic Alzheimer Disease, Donanemab leads to modest slowing of Alzheimer’s progression, Donanemab: bleeding and seizures, Donanemab:'The results may be misleading', Dr Alan Duncan, Dr Margaret McCartney, Dr Peter Gordon, Dr Peter J Gordon, early Alzheimer's disease, early diagnosis, early diagnosis is everywhere, early diagnosis of dementia, Edinburgh, Edinburgh Consensus, Edward R Scheffer Cliff, Eli Lilly, EPAD, Eric L Ross, Estimating the true value: Aducanumab and Donanemab for Early Alzheimer Disease, European Journal of Neurology, Express, FDA, first do no harm, fully informed consent, Gareth Iacobucci, General Medical Council, Glasgow Declaration, GMC, Good Medical Practice, headlines, Henry Simmons, Here’s a game: try and find a doctor’s conflicts of interest., Hide and Seek, Hiding and seeking doctors’ conflicts of interest, Hilary Evans, Hole Ousia, https://www.alzscot.org/conference23, immunoglobulin G1, independent experts or drug representatives in disguise, informed consent, infusion, Issues not considered in the 'Edinburgh Consensus', John R Sims, Key Opinion Leaders, Key opinion leaders and Industry, Keynote Lecture, learning and developments are offering hope for tomorrow, Marc Aurel Busche, Marc S Weinberg, Maree Todd, Mark A Mintun, MCI, Melbourne Dementia Research Centre, MHRA, mild cognitive impairment, Mintun et al, Mirror, monoclonal antibody, Monopoly, MSP, Narrative Controllers, Nature, New treatments for Alzheimer's disease, New York Times, newspaper reports, NICE guidelines, No Holds barred, No sunshine for Scotland, oining the world's first Brain Health Community, paid opinion leaders, paid opinion leaders are a blot on medicine’s integrity and we should make them a thing of the past, PE1493, pharma, Pharmaceutical Industry, Phase 3, placebo-controlled trial of Donanemab, PMCPA, preclinical Alzheimers, preclinical dementia, Prescription Medicines Code of Practice Authority, prevention, primum non nocere, prodromal dementia, Prof Ritchie said: "“We understand the disease, Prof Rob Howard, Prof Robert Howard, Professor Craig Ritchie, Professor Rob Howard, Professor Robert Howard, public health, radio 4, Ray Moynihan, RCPsych, RCT, Realistic Medicine, rebel antiquary, Registers of Interest, regulatory approval, research, Royal College of Psychiatrists, Sara Reardon, scanners, Scott Aytoun, Scottish Brain Sciences, Sebastian Walsh, seizures, side effects, Sky News, Snakes and ladders, snakes ladders and Monopoly, Soeren Mattke, Steven E Arnold, study finds, Sunshine Act for Scotland, Sunshine legislation, t's boom time in industry, tau, The Edinburgh Consensus, the evidence of benefit probably does not outweigh the negatives, The Guardian, The hyperbole in the media and scientific response is unjustified and cruel to patients, The Narrative Controllers, The New England Journal of Medicine, The Rebel Antiquary, The report of the Independent Medicines and Medical Devices Safety Review, The World Tonight, timely diagnosis, timely diagnosis of dementia, Tom Russ, Too much Medicine, trailblazer, TRAILBLAZER-ALZ 2, Transparency, treatments for Alzheimer's disease, University of Cincinnati, US Food and Drug Administration, Vol 617, we understand what is is going on in the brain", worldwide trailblazing headlines of the latest anti-amyloid drug

Posts navigation

Recent Posts

1-202-555-1212

peter@holeousia.com

Pages

About me
being and becoming
in the world
Mind The Gap
where time passes (listen)

Powered by WordPress.com.

Scroll Up

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website